BLISSGVS2024-01-012024-03-31 BLISSGVS2024-01-012024-03-31 BLISSGVS2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member BLISSGVS2024-01-012024-03-31in-bse-fin:OneOperatingExpenses02Member BLISSGVS2024-01-012024-03-31in-bse-fin:OneOperatingExpenses03Member BLISSGVS2024-01-012024-03-31in-bse-fin:OneOperatingExpenses04Member BLISSGVS2024-01-012024-03-31in-bse-fin:OneOperatingExpenses05Member BLISSGVS2024-01-012024-03-31in-bse-fin:OneOperatingExpenses06Member BLISSGVS2024-01-012024-03-31in-bse-fin:OneOperatingExpenses07Member BLISSGVS2024-01-012024-03-31in-bse-fin:OneOperatingExpenses08Member BLISSGVS2024-01-012024-03-31in-bse-fin:OneOperatingExpenses09Member BLISSGVS2024-01-012024-03-31in-bse-fin:OneOperatingExpenses10Member BLISSGVS2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member BLISSGVS2024-01-012024-03-31in-bse-fin:FourOperatingExpenses02Member BLISSGVS2024-01-012024-03-31in-bse-fin:FourOperatingExpenses03Member BLISSGVS2024-01-012024-03-31in-bse-fin:FourOperatingExpenses04Member BLISSGVS2024-01-012024-03-31in-bse-fin:FourOperatingExpenses05Member BLISSGVS2024-01-012024-03-31in-bse-fin:FourOperatingExpenses06Member BLISSGVS2024-01-012024-03-31in-bse-fin:FourOperatingExpenses07Member BLISSGVS2024-01-012024-03-31in-bse-fin:FourOperatingExpenses08Member BLISSGVS2024-01-012024-03-31in-bse-fin:FourOperatingExpenses09Member BLISSGVS2024-01-012024-03-31in-bse-fin:FourOperatingExpenses10Member BLISSGVS2024-03-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 506197 BLISSGVS NOTLISTED Bliss GVS Pharma Limited Equity 2023-04-01 2024-03-31 2024-05-02 2024-04-25 INR Lakhs Yearly 16:00:00 21:45:00 2024-05-02 2024-05-02 true Cash Flow Indirect Declaration of unmodified opinion Single segment Pharmaceutical & Healthcare 2024-01-01 2024-03-31 Audited Standalone 1638174000.00 84638000.00 1722812000.00 784976000.00 0.00 8734000.00 208833000.00 15310000.00 62292000.00 384138000.00 1464283000.00 258529000.00 -410861000.00 -152332000.00 59898000.00 -97622000.00 -37724000.00 0.00 -114608000.00 0.00 0.00 0.00 0.00 -114608000.00 53000.00 -114555000.00 0.00 0.00 104691000.00 1 -1.11 -1.08 0.00 0.00 -1.11 -1.08 0.00 0.00 0.07 1. The above audited financial results which are published in accordance with Regulation 33 of the SEBI Listing Obligations Disclosure Requirements Regulations 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 02 2024. These audited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards Ind AS as prescribed under Section 133 of the Companies Act 2013 read with relevant rules issued thereunder and the other accounting principles generally accepted in India. 2.The above audited financial results for the quarter and year ended March 31 2024 are prepared in compliance with the Ind AS which have been audited by the statutory auditors of the Company. The statutory auditors Kalyaniwalla Mistry LLP have issued audit reports with unmodified opinion on the standalone and consolidated audited financial results. 3. As the Companys business activity falls within a single operating segment viz Pharmaceutical and Healthcare no segment information is disclosed. 4. Employee Benefit Expenses includes Share Based Payment expense on account of ESOP Scheme 2019 of Rs 381.57 Lakh Previous Period Rs 390.43 Lakh as per Ind AS 102 Share based Payment for the year ended March 31 2024. 5.During the year ended March 31 2024 the Company has allotted 538150 equity shares of Rs 1 each fully paid on exercise of stock options by employees in accordance with the Companys ESOP Scheme 2019. From the total 5218000 number of options granted the outstanding number of options as at March 31 2024 are 1757500. 6.The Board of Directors has recommended final dividend of Rs. 0.50 per share. The payment is subject to approval of shareholders in the ensuing Annual General Meeting of the Company. Single segment 2023-04-01 2024-03-31 Audited Standalone 6054597000.00 335005000.00 6389602000.00 3058277000.00 0.00 -63618000.00 825915000.00 58061000.00 235193000.00 1162336000.00 5276164000.00 1113438000.00 -410861000.00 702577000.00 271620000.00 -75492000.00 196128000.00 0.00 506449000.00 0.00 0.00 0.00 0.00 506449000.00 -1536000.00 504913000.00 0.00 0.00 104691000.00 1 0.00 4.85 4.77 0.00 0.00 4.85 4.77 0.00 0.03 0.24 Bad Debts 0.00 Business Development expenses 73750000.00 Corporate Social Responsibility expenses 418000.00 Freight outward 70667000.00 Legal and Professional charges 17223000.00 Other Expenses 108591000.00 Power and Fuel 17822000.00 Repairs and Maintenance 79548000.00 Sales Promotion expenses 7972000.00 Travelling and Conveyance expenses 8147000.00 Bad Debts 105142000.00 Business Development expenses 263652000.00 Corporate Social Responsibility expenses 21154000.00 Freight outward 230489000.00 Legal and Professional charges 43618000.00 Other Expenses 151408000.00 Power and Fuel 88120000.00 Repairs and Maintenance 172530000.00 Sales Promotion expenses 47161000.00 Travelling and Conveyance expenses 39062000.00 3298573000.00 78270000.00 6845000.00 0.00 965000.00 0.00 0.00 0.00 186895000.00 0.00 0.00 58513000.00 245408000.00 41165000.00 124516000.00 3795742000.00 894529000.00 0.00 3995083000.00 138745000.00 1554443000.00 360299000.00 200911000.00 6249481000.00 24460000.00 561329000.00 7729799000.00 0.00 0.00 11525541000.00 104691000.00 9779747000.00 9884438000.00 9884438000.00 350953000.00 0.00 92374000.00 443327000.00 24697000.00 0.00 0.00 0.00 468024000.00 305363000.00 544660000.00 251540000.00 1101563000.00 66145000.00 0.00 5371000.00 0.00 1173079000.00 0.00 0.00 1641103000.00 11525541000.00 7.The Board of Directors of the Company in its meeting held on February 16 2024 has approved an internal restructuring of foreign subsidiaries of the Company to create synergies across the business, strengthen capital structure and establish the leaner structure of the Company at the group level without any change in ultimate ownership of the Company over the subsidiaries. The following approved by the Board of Directors has been carried out. a.Change in Ownership by way of transfer of entire equity stake of Asterisk Lifesciences GH Limited held by Asterisk Lifesciences Limited UK a wholly owned subsidiary of the Company to Bliss GVS International Pte. Ltd. Singapore a wholly owned subsidiary of the Company on February 29 2024. b.Voluntary Liquidation of Asterisk Lifesciences DRC a stepdown subsidiary of the Company in the Democratic Republic of Congo due to macroeconomic business scenarios. As the Company has appointed liquidator the Company has lost control of Asterisk Lifesciences DRC from the date the liquidator is appointed and thus the Group has impaired the investments and loans aggregating to Rs 117.46 Lakh in the books of Bliss GVS International Pte Limited Singapore and has derecognised the step-down subsidiary from Consolidation w.e.f February 19 2024. c.Conversion of the loan USD 5000000 Rs 4151.88 Lakh granted by the Company to Bliss GVS International Pte. Ltd. Singapore a wholly owned subsidiary of the Company into Equity Shares on February 23 2024 . 8.The Company has invested in given loans accrued interest and due thereon and trade receivables from one of its subsidiary and its stepdown subsidiaries aggregating to Rs 15255.83 Lakh. This subsidiary have a consolidated negative net worth as at March 31 2024. In view of macroeconomics business scenarios the management has assessed these investments and loans for impairment and based thereof investments loan in given to Companys subsidiary Bliss GVS International Pte Ltd including stepdown subsidiaries viz Greenlife Bliss Healthcare Ltd Asterisk Lifesciences DRC and Asterisk Lifesciences GH Ltd have been impaired and accordingly an amount of Rs 4108.61 Lakh in standalone and Rs 2919.61 Lakh in consolidated financial statements has been recognised as an exceptional item. 9.The figures for the quarter ended March 31 are the balancing figures between audited figures in respect of the year ended March 31 and the published year to date unaudited figures for the nine months ended December 31 of the respective financial year. 58061000.00 -223385000.00 -168388000.00 0.00 103974000.00 0.00 408120000.00 0.00 0.00 -210843000.00 0.00 15383000.00 0.00 235193000.00 410861000.00 0.00 0.00 71645000.00 0.00 34003000.00 1260000.00 133794000.00 38157000.00 0.00 0.00 -3378000.00 0.00 215706000.00 0.00 850055000.00 1552632000.00 0.00 0.00 0.00 293407000.00 0.00 1259225000.00 123350000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2538000.00 386768000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1260000.00 58578000.00 0.00 -894865000.00 0.00 -1095907000.00 0.00 0.00 23140000.00 0.00 0.00 0.00 355000.00 0.00 144884000.00 245705000.00 0.00 26489000.00 53409000.00 50367000.00 0.00 0.00 -207591000.00 -44273000.00 0.00 -44273000.00 186019000.00 141746000.00 71000.00 -2053000.00 18000.00 -517000.00 0.00 0.00